While minimal residual disease (MRD) has been a topic of research for at least a decade, right now it is more top of mind than ever before for people treating cancer, said C. Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer.
While minimal residual disease (MRD) has been a topic of research for at least a decade, right now it is more top of mind than ever before for people treating cancer, said C. Ola Landgren, MD, PhD, professor of medicine and chief of the Myeloma Service at Memorial Sloan Kettering Cancer.
Transcript
How is our understanding of MRD and what it means for treatment decisions evolving?
Minimal residual disease is a topic that is on everybody's lips these days. You cannot attend one single meeting without hearing about the minimal residual disease [MRD] testing in myeloma and other diseases, as well. I have worked on it for more than 10 years, and we worked on it in the laboratory. We have used flow cytometry-based, we have used PCR [polymerase chain reaction]-based, we have done next generation sequencing based, we have done proteomic-based [testing], and we also have started doing immuno-PET—based imaging for minimal residual disease.
All the data in multiple myeloma that has been generated from larger studies show that if you treat a newly diagnosed patient and he or she obtains him MRD negativity, that's probably the strongest prognostic factor for a long progression-free survival. And there is that even showing that it could be a prognostic factor associated with long overall survival. We published the first meta-analysis back in 2016, and there was a subsequent meta-analysis in 2017, using very similar data sets, plus some additional older data sets, as well. So, there are 2 meta-analyses in showing in myeloma that MRD is very important, prognostically.
There is not yet any study that has been published that's designed to use MRD for decision making, but there are several ongoing studies, we have at our center, as well, looking at the role of MRD as a decision tool to determine whether therapy could be increased in intensity or decreased or could you even use patients that are MRD negative for many years and use that MRD to determine whether patient potentially could even be stopped for therapy. So, those are studies that are ongoing, and it will be very interesting to see what the data shows.
Persistence Pays Off With Zanubrutinib: A Challenging CLL Case With a Prior BTK Inhibitor Failure
May 10th 2024The case of a 77-year-old woman with a long chronic lymphocytic leukemia (CLL) history illustrates the novel use of zanubrutinib as a potential option for some patients who have failed first-generation Bruton tyrosine kinase (BTK) inhibitors and venetoclax.
Read More
Frameworks for Advancing Health Equity: Urban Health Outreach
May 9th 2024In the series debut episode of "Frameworks for Advancing Health Equity," Mary Sligh, CRNP, and Chelsea Chappars, of Allegheny Health Network, explain how the Urban Health Outreach program aims to improve health equity for individuals experiencing homelessness.
Listen
CMS Medicare Final Rule: Advancing Benefits, Competition, and Consumer Protection
May 7th 2024On this episode of Managed Care Cast, we're talking with Karen Iapoce, senior director of government products and programs at ZeOmega, about the recent CMS final rule on Medicare Part D and Medicare Advantage.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More